Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. (Q48300537)

10 February 2018

title

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. (English)

1 reference

10 February 2018

0 references

1 reference

Christoph Hock

1

1 reference

10 February 2018

Uwe Konietzko

2

1 reference

10 February 2018

Johannes R Streffer

3

1 reference

10 February 2018

Jay Tracy

4

1 reference

10 February 2018

Andri Signorell

5

1 reference

10 February 2018

Britta Müller-Tillmanns

6

1 reference

10 February 2018

Ulrike Lemke

7

1 reference

10 February 2018

Katharina Henke

8

1 reference

10 February 2018

Eva Moritz

9

1 reference

10 February 2018

Esmeralda Garcia

10

1 reference

10 February 2018

M Axel Wollmer

11

1 reference

10 February 2018

Daniel Umbricht

12

1 reference

10 February 2018

Dominique J F de Quervain

13

1 reference

10 February 2018

Marc Hofmann

14

1 reference

10 February 2018

Alessia Maddalena

15

1 reference

10 February 2018

Andreas Papassotiropoulos

16

1 reference

10 February 2018

Roger M Nitsch

17

1 reference

10 February 2018

language of work or name

English

0 references

publication date

1 May 2003

1 reference

10 February 2018

published in

Neuron

1 reference

10 February 2018

volume

38

1 reference

10 February 2018

page(s)

547-554

1 reference

10 February 2018

issue

4

1 reference

10 February 2018

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Unusual spectral energy distribution of a galaxy previously reported to be at redshift 6.68.

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Alzheimer's disease: treatments in discovery and development

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

1 reference

7 January 2021

Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Functional disability in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Alzheimer disease therapy: can the amyloid cascade be halted?

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Disordered proteins in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

The Clinical Dementia Rating (CDR): current version and scoring rules

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Alzheimer's disease: genes, proteins, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

A safer vaccine for Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in?

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Intramembrane proteolysis by presenilins

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

The cell biology of Alzheimer's disease: uncovering the secrets of secretases

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

Inflammation and therapeutic vaccination in CNS diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0896-6273%2803%2900294-0

7 January 2021

10.1016/S0896-6273(03)00294-0

Identifiers

DOI

1 reference

10 February 2018

PubMed ID

12765607

1 reference

10 February 2018